ArticleNpj viruses2025
Therapeutic potential of Shigella phage SSG23 against Shigella sonnei biofilms and in BALB/c mice.
Article in Npj viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Isolation of novel phages from a resistant Dorea longicatena strain reveals genes associated with phage resistance.Npj viruses · 2026Article
- Isolation, Identification, Biological Characteristics, and In Vitro and In Vivo Antibacterial Effects of a Bovine-DerivedMicroorganisms · 2026Article
- Bacteriophage Therapy AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Isolation and characterization of lyticFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant (MDR) Shigella spp. threaten global health, renewing interest in phage therapy. Here, we report the isolation and characterization of a novel lytic phage, SSG23, effective against four major Shigella serovars. Phage SSG23 possesses a prolate head and contractile tail, consistent with the Straboviridae family, and remains stable across a broad pH (4-11) and temperature range (-20 °C to 50 °C). It exhibits a latent period of 37 minutes, a burst size of 195 plaque-forming units per cell, and a 168,820 bp dsDNA genome with 40.8% GC content lacking resistance or toxin genes. SSG23 efficiently degrades biofilms, alone or with antibiotics, and is non-toxic to macrophages in vitro. In S. sonnei-infected BALB/c mice, oral administration reduced bacterial colonization and shedding while improving health without evidence of resistance emergence. Neutralizing antibodies developed in mice, yet the phage maintained its efficacy. These findings support SSG23 as a promising candidate for phage therapy against Shigella infection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.